GLP-1 / metabolic

Lixisenatide

FDA-approved

Adlyxin, Lyxumia · GLP-1 receptor agonist (short-acting)

Short-acting prandial GLP-1 agonist for type 2 diabetes.

Half-life

~3 hours (daily)

Route

Subcutaneous daily

Evidence

FDA-approved — type 2 diabetes.

What it is

A once-daily short-acting GLP-1 agonist with strong effects on gastric emptying and post-meal glucose; the US standalone was discontinued but it remains in Soliqua.

How it works

GLP-1 agonism with pronounced gastric-emptying delay blunts postprandial glucose plus insulinotropic and glucagon-suppressing effects.

Studied for

Postprandial glycemic control in T2D; CV safety shown (ELIXA).

Regulatory status

FDA-approved; standalone withdrawn in US (available in Soliqua).

Safety

GI effects common; hypoglycemia risk with insulin/sulfonylureas; pancreatitis caution.

Reconstitution calculator →

Educational information only — not medical advice, and not a recommendation to use any compound. Many peptides here are not approved for human use; legal status and evidence quality vary and are noted above. This page contains no dosing information. Consult a qualified clinician before making any health decision.